Author/Authors :
RAZMANDEH, Rezvan Diabetes Research Center - Endocrinology and Metabolism Clinical SciencesInstitute - Tehran University of Medical Sciences, Tehran, Iran , TOOTEE, Ali Diabetes Research Center - Endocrinology and Metabolism Clinical SciencesInstitute - Tehran University of Medical Sciences, Tehran, Iran , RAZI, Farideh Diabetes Research Center - Endocrinology and Metabolism Clinical SciencesInstitute - Tehran University of Medical Sciences, Tehran, Iran , RAMBOD, Camelia Diabetes Research Center - Endocrinology and Metabolism Clinical SciencesInstitute - Tehran University of Medical Sciences, Tehran, Iran , LARI-JANI, Bagher Endocrinology and Metabolism Research Center - Endocrinology and Metabolism Clinical Sciences Institute - Tehran University of Medical Sciences, Tehran, Iran , NASLI ESFAHANI, Ensieh Diabetes Research Center - Endocrinology and Metabolism Clinical SciencesInstitute - Tehran University of Medical Sciences, Teh-ran, Iran
Abstract :
Background: Stem-cell therapy plays a preventive role for different complications of diabetes, including diabetes nephropathy. The current phase 3 single-arm clinical trial is designed to investigate the potential protective effect of allotransplantation of fetal liver-derived cell suspension in diabetic nephropathy.
Methods: Seventy-four diabetic patients with type 1 were selected according to the inclusion criteria defined and un-derwent the procedure of transplantation fetal liver-derived stem-cells. Patients were followed for a period on 24 months and indicators of diabetes and diabetes nephropathy (HbA1C, ACR, Cr and GFR) were monitored during the whole time. Statistical analysis was conducted with SPSS Vers.16 and one-way repeated measure ANOVA was used.
Results: The GFR values significantly increased during the 24 months period of follow up.
Conclusion: Stem-cell therapy can play a significant protective role in prevention from diabetic nephropathy.
